Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(4)

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NYGxO4pOS3m2b4TvfIlkyqCjc4PhfS=> MUG0PEBp M3zpeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u NYnvNWtXOjF|OEixPVE>
human colon cancer cell line (LoVo cells) NF3wclFRem:uaX\ldoF1cW:wIHHzd4F6 NFH3Vm9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v MWOxNVU6OTVyNR?=
human LoVo cells M3O1cnBzd2yrZnXyZZRqd25iYYPzZZk> M{fJW|Q5KHSxIEeyJIg> NX[xSWkxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? Mo\NNlIyQDJ7Mkm=
P19 cells M1fScWZ2dmO2aX;uJIF{e2G7 NFy1O5JKdmirYnn0bY9vKG:oIGDsZZRmdGW2LXTldol3\WRiZ4Lve5RpKG[jY4TvdkBz\WOncITvdkBqdiCSMUmgZ4VtdHNuIFnDOVA:OC5yMEKg{txONg>? M1XWZVE2PzdzNEG5
human BJ cells NHXteG1EgXSxdH;4bYPDqGG|c3H5 NXXyeZlrPzJiaB?= MkHzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OC5yMEKg{txONg>? NHjpbpAzOjl{MUC4NS=>
human HT-29 cells NEjuSWhHfW6ldHnvckBie3OjeR?= NITNRVEzKGh? NHr4PZFG\m[nY4Sgc44hdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygbY4hcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgNkBpenNidYPpcochUkNvMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViYYPzZZk> MYSyNVQzQDN5NR?=
human A549 cells MnuzR5l1d3SxeHnjxsBie3OjeR?= MUm3NkBp MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\A>? MUWxPFQ5PDd5NR?=
human HT-29 cells MoXXSpVv[3Srb36gZZN{[Xl? NWPx[FlGUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P MY[yNVUyOzJ7Mx?=
human HT-29 cells M1fjeGZ2dmO2aX;uJIF{e2G7 MXuyJIg> M2PudWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSGStNlkh[2WubIOgZZN{\XO|ZXSgdoVlfWO2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIFnfGW{IEKgbJJ{KGK7IIXzbY5oKEqFMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViY3XscE1j[XOnZDDhd5NigSxiRVO1NF0zNjZibl2u NXTGO|VDOjF7N{OxNFE>
Sf9 cells MVTGeY5kfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJHN6cyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUOgcm0v M{P3clE5QDJ|N{i0
human HUVEC NXS1WYU6WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVG0PEB1dyB5MjDo MlizRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 MWiyNlE5Ojl{OR?=
P19 cells M3zsZWZ2dmO2aX;uJIF{e2G7 NFfm[HBKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v NHvZbWwyPTd5MUSxPS=>
Sf9 cells NGroXYhHfW6ldHnvckBie3OjeR?= MorKTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJI1qdiCkeTDFUGlUSSCrbjDwdoV{\W6lZTDv[kAyKHWvb3yvUEBCXFB? NGTxRVQyPzNzNUi1Ny=>
Sf21 cells MlrUSpVv[3Srb36gZZN{[Xl? MnrNTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u NEXQZmIyPzB6OEC1PS=>
human colon carcinoma cell line HCT116 NUL3R5h3TnWwY4Tpc44h[XO|YYm= NX;zTGNoS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MWCxOVU{PzN2NR?=
human ST486 cells NVThS4lWWHKxbHnm[ZJifGmxbjDhd5NigQ>? NEfHcoY1QCC2bzC3NkBp MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? NXrTfIJ3OjJzOEK5Nlk>
human MDA-MB-231 cells NVHi[oJuS3m2b4TvfIlkyqCjc4PhfS=> NGjQWFM4OiCq M3XWemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= NHH1Oo0yQDR6NEe3OS=>
P19 cells M{DNXmZ2dmO2aX;uJIF{e2G7 MXjJcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u MWWxOVc4OTRzOR?=
human DLD1 cells M4HpWHBzd2yrZnXyZZRqd25iYYPzZZk> MkWxOFguPzJiaB?= NVHBcIRrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEUGQyKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QSCwTT6= MWKyNlE5Ojl{OR?=
insect cells MWTGeY5kfGmxbjDhd5NigQ>? MoXITY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSaX2xJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkhUFSURjygTWM2OD1zMDDuUU4> Mn;2NVkyPzlyN{[=
V79 MZ cells MkjHSpVv[3Srb36gZZN{[Xl? NEjYb2FKdmirYnn0bY9vKG:oIHj1cYFvKGGuZH;zeIVzd26nIIP5cpRp[XOnIHX4dJJme3OnZDDpckBXPzliTWqgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHTvd5Rmem:wZTDzfY51cGW|aYOsJGlEPTB;MUGgcm0v Mn71NlQ1OjJ3MUm=
P19 cells NFqzcm9HfW6ldHnvckBie3OjeR?= NXfVRXRCUW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IHnuJHAyQSClZXzsd{whUUN3ME2xOEBvVS5? MYCxOVc4OTRzOR?=
Sf9 cells M2TiOWZ2dmO2aX;uJIF{e2G7 NEDMS24zOCCvaX7z NIKwUWlKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFIxKG2rboOgZpkhTUyLU1GgbY4heHKnc3XuZ4Uhd2ZiMTD1cY9tN0xiQWTQMEBKSzVyPUG1JI5ONg>? M{SwR|E4OzF3OEWz
human PBMC NW[ycYVWTnWwY4Tpc44h[XO|YYm= MWiyOEBp MlHEV5VxeHKnc4Ppc44hd2ZiSVyyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUC9NVYhdk1w NHG0XZgyQDV6NUC0Oi=>
human A549 cells MUTDfZRwfG:6aXRCpIF{e2G7 M1LEWVQ5KGh? MoXVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2yNEBvVS5? NUfpUFFWOjV6MkW5N|Q>
human CEM cells Mk\6R5l1d3SxeHnjxsBie3OjeR?= MUG3NkBp NH7WVVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NIiwVngzOjl{MUC4NS=>
human HeLa cells NWXs[YJtS3m2b4TvfIlkyqCjc4PhfS=> NXzkZ49LPDhiaB?= NUjNV5hlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?= MYeyOVgzPTl|NB?=
human PC3 cells Ml;qR5l1d3SxeHnjxsBie3OjeR?= M4j3SFQ5KGh? MkPBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? NIns[VIzPTh{NUmzOC=>
human SF268 cells Mnn6R5l1d3SxeHnjxsBie3OjeR?= NX\WRlM4PDhiaB?= NX7sb3dzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= M1fZc|IyPTF|Mkm0
human MCF7 cells MVLDfZRwfG:6aXRCpIF{e2G7 NHThO5I1QCCq M13XO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? M3TudFIyOzh6MUmx
HEK293 cells MlfmR5l1d3SxeHnjxsBie3OjeR?= NGH2ZlI4OiCq NUP2d2ZqS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NETMZXUzPDd4M{K2Ni=>
HUE cells NFrHfGhHfW6ldHnvckBie3OjeR?= NIHTeHQ6OCCvaX7z MlSxTY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iSGXFJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hfHKnYYTl[EBnd3JiOUCgcYlveyCkZX\vdoUhXkWJRjDjbIFtdGWwZ3WgZpkhTUyLU1GsJGlEPTB;N{Cgcm0v MYWyNFE4ODF4Mx?=
human A431 cells NHq4W3ZEgXSxdH;4bYPDqGG|c3H5 MYSyOEAhcA>? M3;uW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= M1TVSlIzPTRzMEWx
human Jurkat cells NGj1[IZRem:uaX\ldoF1cW:wIHHzd4F6 NXTNeHlGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> MXOxPVQzPzJyMx?=
HEK293 cells NGLteoJHfW6ldHnvckBie3OjeR?= MkSxTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? MYGxOVc4OTRzOR?=
human KE-97 cells M3fDeGN6fG:2b4jpZ:Kh[XO|YYm= M3TvSVczKGh? M{WxNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> M2jFTlI1OzJ6Mkiz
human CHOK1 cells M{flWmN6fG:2b4jpZ:Kh[XO|YYm= NEnYZZI1QCCq NX3CeVR5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0iRS{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMUOg{txONg>? MWKyNVUyOzJ7NB?=
mouse NIH/3T3 cells NYqwfoF6S3m2b4TvfIlkyqCjc4PhfS=> NE\iSlg6PiCq MnnxR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u M3;3eFI1OzZzNUKx
human A2780 cells MXLDfZRwfG:6aXRCpIF{e2G7 MYW5OkBp MnLBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NVzudoVROjR|NkG1NlE>
human 8505C cells MknqR5l1d3SxeHnjxsBie3OjeR?= NX\6R2F7QTZiaB?= MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC4OVA2SyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w M2rDfFI1OzZzNUKx
human 518A2 cells NH3CSoZEgXSxdH;4bYPDqGG|c3H5 M4D1UVk3KGh? M3PkUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> MUCyOFM3OTV{MR?=
human HuH7 cells M1zRW2N6fG:2b4jpZ:Kh[XO|YYm= NUTITIhKPzJiaB?= M1X2e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOyEQvF2u NXHjeYR{OjR|MkiyPFM>
FL5.12-Akt1 cells M4fFb3Bzd2yrZnXyZZRqd25iYYPzZZk> NGmzPHFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> NYjWfog{OTZ2MEO2NlY>
human MiaPaCa-2 cells NFTHd3BRem:uaX\ldoF1cW:wIHHzd4F6 NV3S[YlQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNbYFR[UOjLUKgZ4VtdHNuIFnDOVA:OC5|NzFOwG0v NY\OeZl4OTZ2MUO3PFA>
human BGC823 cells MnLqR5l1d3SxeHnjxsBie3OjeR?= NEj3WFg4OiCq MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u NGTKcHgzPDN{OEK4Ny=>
human MCF7 cells MX7DfZRwfG:6aXRCpIF{e2G7 NHW1NnQ6PiCq MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? NX;qO2E5OjR|NkG1NlE>
human A549 cells NFHFTVNEgXSxdH;4bYPDqGG|c3H5 MlTyPVYhcA>? NULtXXJoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NYL2dmtpOjR|NkG1NlE>
HEK293 cells MXfDfZRwfG:6aXRCpIF{e2G7 M1;MeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczygSWM2OD1{IN88UU4> NF\aRXczPTNzNkOxOy=>
human Raji cells  M{DXXWN6fG:2b4jpZ:Kh[XO|YYm= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSZYpqKGOnbHzzMEBGSzVyPUKg{txONg>? M2GxblI2OzF4M{G3
human HepG2 cells MUTDfZRwfG:6aXRCpIF{e2G7 NWK3b4F6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u MnKwNlU{OTZ|MUe=
human BJ cells NXzyPIhxS3m2b4TvfIlkyqCjc4PhfS=> MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> NV2zbZFwOjV|MU[zNVc>
human U937 cells MUPDfZRwfG:6aXRCpIF{e2G7 NEPudYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{NCCLQ{WwQVIh|ryPLh?= M2TaWFE4ODh6ME[3

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID